FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/02/2024
Back to search
Official data from USPTO
LTZ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
10/02/2024
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
10/14/2022
Registration date
07/02/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/02/2024
Last transaction
07/02/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
US
Examiner
CLARK, MICHAEL J.
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of wording "LTZ" and a stylized device. The device is composed of three group of lines, with each group consisting of three parallel lines, and each group of lines touching with an inner line of another group of lines at an approximately middle position, therefore forming a closed triangle.
Holders and representatives
Holders
LTZ Therapeutics Inc.
Shenzhen Zean Biomedical Co., Ltd.
Representatives
Nazly Aileen Bayramoglu BAYRAMOGLU LAW OFFICES LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes for the treatment of cancersneoplasmsautoimmune diseasesinfectious diseases; drugs for medical purposesimmunopotentiating drugsimmunosuppressive agentsmedicines for tumor suppression; biochemical medicines for the treatment of cancersneoplasmsautoimmune diseasesinfectious diseases; biological preparations for medical purposes for the treatment of cancersneoplasmsautoimmune diseasesinfectious diseases; pharmaceutical preparations for treating cancersneoplasmsautoimmune diseasesinfectious diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; immunostimulants; pre-filled syringes with pharmaceutical preparations for the treatment of cancersneoplasmsautoimmune diseasesinfectious diseases for medical purposes; injectable solutions in the nature of immunopotentiating drugsimmunosuppressive agentsmedicines for tumor suppression for medical purposes; pharmaceutical preparations for activating cellular function; tumor suppressing agents; anti-cancer preparations; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer
Publications
History of USPTO decisions and trademark events.
30 publications found
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/08/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/02/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/18/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/17/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/16/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/16/2024
PUBO
PUBLISHED FOR OPPOSITION
04/16/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/27/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/27/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/27/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/17/2024
RFNT
REFUSAL PROCESSED BY IB
10/11/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/14/2023
RFRR
REFUSAL PROCESSED BY MPU
09/14/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/24/2023
CNRT
NON-FINAL ACTION WRITTEN
08/23/2023
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
08/23/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/01/2023
CNRT
NON-FINAL ACTION WRITTEN
07/31/2023
DOCK
ASSIGNED TO EXAMINER
07/30/2023
CHLD
CHANGE OF OWNER RECEIVED FROM IB
03/19/2023
MAFR
APPLICATION FILING RECEIPT MAILED
01/24/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/20/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/19/2023
Continuous trademark protection
Get notified about every new filing that threatens LTZ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.